Similar articles

• Antimicrobial activity and pharmacokinetics/pharmacodynamics of the novel glycylcycline, tigecycline.

  Peterson LR. Peterson LR. Diagn Microbiol Infect Dis. 2005 Jul;52(3):163-4. doi: 10.1016/j.diagmicrobio.2005.06.011. Diagn Microbiol Infect Dis. 2005. PMID: 16105559 No abstract available.
• Inhibitors of protein synthesis.

  Leviton I. Leviton I. Cancer Invest. 1999;17(1):87-92. Cancer Invest. 1999. PMID: 10999052 Review. No abstract available.
• [Tigecycline, the first of a new class of antibiotics: the glycylcyclines].

  Bosó-Ribelles V, Roma-Sánchez E, Salavert-Lletí M, Hernández-Martí V, Poveda-Andrés JL. Bosó-Ribelles V, et al. Rev Esp Quimioter. 2007 Mar;20(1):19-35. Rev Esp Quimioter. 2007. PMID: 17530033 Review. Spanish. No abstract available.
• Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines.

  Tuckman M, Petersen PJ, Projan SJ. Tuckman M, et al. Microb Drug Resist. 2000 Winter;6(4):277-82. doi: 10.1089/mdr.2000.6.277. Microb Drug Resist. 2000. PMID: 11272255
• Tigecycline resistance in Australian antibiotic-resistant Gram-negative bacteria.

  Iredell J, Thomas L, Power D, Mendes E. Iredell J, et al. J Antimicrob Chemother. 2007 Apr;59(4):816-8. doi: 10.1093/jac/dkm002. Epub 2007 Mar 12. J Antimicrob Chemother. 2007. PMID: 17353224 No abstract available.